UK Government to invest $764m into new health data service
The UK Government has announced a £600m ($764m) funding pot to create a new Health Data Research Service, reducing red …
-
-
EU president to meet pharma leaders as tariff threat looms
European Commission (EC) President Ursula von der Leyen is set to hold talks with senior pharmaceutical executives today (8 April), …
-
Ethris and Lonza to develop mRNA vaccines for respiratory conditions
Ethris has partnered with contract development and manufacturing organisation Lonza for the development of room-temperature stable mRNA vaccine candidates targeting …
-
Africa: The clinical impact of the US withdrawal from WHO and USAID
The clinical supply chain in Africa is striving to manage the impact of the US decision to withdraw from the …
-
EC approves extension of indication for Janssen-Cilag’s Darzalex
The European Commission (EC) has approved the extension of indication for Janssen-Cilag International’s Darzalex (daratumumab) subcutaneous (SC) formulation to be …
-
AD/PD 2025: Reporting of first real-world data for Leqembi focuses on operational challenges and safety
Following the launch of the first disease-modifying therapies for Alzheimer’s disease, a key theme at the AD/PD 2025 International Conference …
-
RFK Jr shifts stance on MMR vaccine amid measles deaths
US health secretary Robert F Kennedy Jr has made his most direct endorsement to date of the measles, mumps, and …
-
AD/PD 2025: First real-world data report for Leqembi focuses on operational challenges
Following the launch of the first disease-modifying therapies for Alzheimer’s disease, a key theme at the AD/PD 2025 International Conference …
-
Rhythm seeks market expansion for Imcivree following Phase III victory
Rhythm Pharmaceuticals is pursuing approval for its rare obesity disorder drug Imcivree in acquired hypothalamic obesity after it showed a …
-
China’s NMPA authorises Santen’s glaucoma treatment application
China’s National Medical Products Administration (NMPA) has approved the marketing authorisation application of Santen Pharmaceutical's Tapcom to treat individuals with …
-
Obesity drugs won’t be covered by Medicare under 2026 CMS policy
The US Centers for Medicare & Medicaid Services (CMS) confirmed that it will not proceed with a Biden administration proposal …
-
EC approves AstraZeneca’s Imfinzi combo for NSCLC
The European Commission (EC) has granted approval for AstraZeneca's Imfinzi plus chemotherapy for treating resectable non-small cell lung cancer (NSCLC) …
-
ABL Bio and GSK link on neurodegenerative conditions
ABL Bio has announced a global licensing agreement with GSK, allowing the latter to develop medicines for neurodegenerative conditions. Through this …
-
Uveitis market expected to reach $1.5bn across 7MM by 2033
The uveitis market is expected to grow at a compound annual growth rate of 10.9% throughout the forecast period (2023 …
-
Daiichi and AstraZeneca’s Enhertu gains EC approval for breast cancers
The European Commission (EC) has approved Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) for use as a single agent to …
